AstraZeneca: Tezspire antiasthmatic approved in the USA


(CercleFinance.com) – AstraZeneca announced Monday that the marketing of Tezspire, the new asthma treatment it developed with the American Amgen, had been authorized in the United States.

The pharmaceutical company specifies that the green light from the FDA concerns the use of the drug as an adjunct to severe asthma in adults and children over 12 years old.

After phase III clinical trials in which Tezspire had demonstrated its effectiveness in addition to existing treatments, the drug had obtained a status of ‘priority review’ with the FDA.

Tezspire belongs to a new category of asthma medication which acts on the inflammatory process by targeting thymic stromal lymphopoietin (TSLP), a cytokine that plays a key role in allergic reactions.

Copyright © 2021 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.

Facebook
Linkedin
E-mail





Source link -85